Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.32 |
| ▸ | DPP4 | P27487 | 4/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.32 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | TLR2 | O60603 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.30 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.30 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614414 | 0.86 | GSR (0.44) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL1168277 | 0.86 | GSR (0.44) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL1168594 | 0.86 | GSR (0.44) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL1167729 | 0.86 | GSR (0.44) | GSRGNAI3GNAO1GNAI1DPP7 | |
| Lysine SCHEMBL27751664 | 0.84 | GSR (0.56) | GSRUSP2SLCO1B1 | |
| SCHEMBL1895771 | 0.83 | GSR (0.37) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL1168214 | 0.82 | GSR (0.38) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL1167730 | 0.78 | GSR (0.37) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL1168908 | 0.78 | GSR (0.42) | GSRGNAI3GNAO1GNAI1DPP7 | |
| SCHEMBL3957957 | 0.75 | GSR (0.37) | GSRGNAI3GNAO1GNAI1DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615528-B2 | Methods for alleviating deleterious effects of 3-deoxyglucosone | FOX CHASE CANCER CENTER (US) | 2009-11-10 | — | — | US | claimed |
| US-20070270335-A1 | METHODS FOR ALLEVIATING DELETERIOUS EFFECTS OF 3-DEOXYGLUCOSONE | BROWN TRUMAN R | 2007-11-22 | — | — | US | claimed |
| US-20060247155-A1 | Methods for alleviating deleterious effects of 3-deoxyglucosone | BROWN TRUMAN R | 2006-11-02 | — | — | US | claimed |
| US-20060241023-A1 | Methods for alleviating deleterious effects of 3-deoxyglucosone | BROWN TRUMAN R | 2006-10-26 | — | — | US | claimed |
| US-7071298-B2 | Compounds and methods for treating glycogen storage disease and other pathological conditions resulting from formation of age-proteins | FOX CHASE CANCER CENTER (US) | 2006-07-04 | — | — | US | claimed |
| US-20020111291-A1 | Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention | THE INSTITUTE FOR CANCER RESEARCH | 2002-08-15 | — | — | US | claimed |
| US-20110112188-A1 | Treatment of Inflammatory Conditions | DYNAMIS THERAPEUTICS, INC. | 2011-05-12 | — | — | US | disclosed |
| JP-2011026322-A | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS INC | 2011-02-10 | — | — | JP | disclosed |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | DYNAMIS THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7749503-B2 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7671019-B2 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7622117-B2 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20070021357-A1 | Treatment of inflammatory conditions | DYNAMIS THERAPEUTICS, INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2006138609-A2 | TREATMENT OF INFLAMMATORY CONDITIONS | DYNAMIS THERAPEUTICS, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-1576093-A2 | 3-DEOXYGLUCOSONE AND SKIN | Dynamis Therapeutics, Inc. (US) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005079463-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | DYNAMIS THERAPEUTICS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | disclosed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| WO-2003089601-A2 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111291-A1 | Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention | FANCF, FANCI, AGER | GSR 1007/4885GNAI3 2203/4885GNAO1 2954/4885 |
| US-20100297046-A1 | Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors | FN3K, ROS1, FN3KRP | GSR 712/4885GNAI3 1237/4885GNAO1 1331/4885 |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DPM1, G6PD, UGGT1 | GSR 1409/4885GNAI3 1883/4885GNAO1 804/4885 |
| US-20060247155-A1 | Methods for alleviating deleterious effects of 3-deoxyglucosone | AGER, ALDOA, FBP1 | GSR 314/4885GNAI3 2273/4885GNAO1 1715/4885 |
| US-20070270335-A1 | METHODS FOR ALLEVIATING DELETERIOUS EFFECTS OF 3-DEOXYGLUCOSONE | AGER, ALDOA, FBP1 | GSR 295/4885GNAI3 2303/4885GNAO1 1720/4885 |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DPM1, G6PD, UGGT1 | GSR 1409/4885GNAI3 1883/4885GNAO1 804/4885 |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | AGER, GLA, GALE | GSR 138/4885GNAI3 1783/4885GNAO1 772/4885 |
| US-20060241023-A1 | Methods for alleviating deleterious effects of 3-deoxyglucosone | AGER, ALDOA, FBP1 | GSR 297/4885GNAI3 2253/4885GNAO1 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.